礼来牵手 Hims & Hers 销售减肥药：Foundayo 每月149美元起，Zepbound 每月299美元起
总部位于 Indianapolis 的礼来公司（Eli Lilly）与远程医疗平台 Hims & Hers Health 11月6日宣布达成协议，扩大患者获得礼来减肥药的渠道。符合条件的患者在 Hims & Hers 平台上经持牌医疗提供者开具处方后，可以直接在该平台内按与任何患者相同的自费价格购买 Zepbound（tirzepatide）与 Foundayo（orforglipron），不必再跳转到礼来自己的自费平台。
两家公司公布的自费价为：每日口服的 Foundayo 每月149美元起，每周注射一次的 Zepbound 每月299美元起，与礼来 LillyDirect 平台的价格一致。患者可以在 Hims & Hers 平台上完成咨询、由医疗提供者判断是否适合开药，并把经美国食品药品监管局（FDA）批准的礼来药物直接寄送到家。
礼来执行副总裁兼礼来美国总裁 Ilya Yuffa 表示，礼来一直在寻找新办法，让更多人获得他们需要的药物，也就是到患者已经所在的地方去；数以百万计的人在 Hims & Hers 寻求诊疗，通过这一协议，这些患者如今有了一条更简单、更直接的途径，在获开处方时以可负担的价格获得 FDA 批准的礼来药物。
Hims & Hers 联合创始人兼首席执行官 Andrew Dudum 表示，他为 Hims & Hers 能参与让更多人获得礼来所创造的药物而感到自豪。协议还约定，Hims & Hers 从未提供礼来 GLP-1 药物的配制仿制品，并承诺今后也不会提供；两家公司同时承诺保护独立的临床决策，使平台上的医疗提供者继续为每位患者开出其认为恰当的治疗。
据路透社报道，这项协议公布后，Hims & Hers 股价在盘前交易中上涨逾7%。礼来方面此前只能让 Hims & Hers 平台上的患者离开该平台、前往 LillyDirect 购买其药物。
Lilly Teams With Hims & Hers to Sell Obesity Drugs: Foundayo From $149 a Month, Zepbound From $299
Eli Lilly and Company, based in Indianapolis, and telehealth platform Hims & Hers Health announced an agreement on November 6 to expand access to Lilly's obesity medicines. Under the agreement, eligible patients who receive a prescription from a licensed provider on the Hims & Hers platform will be able to buy Zepbound (tirzepatide) and Foundayo (orforglipron) at the same self-pay prices available to any patient, without leaving the platform for Lilly's own cash-pay site.
Self-pay pricing starts at $149 per month for Foundayo, a daily oral medicine, and $299 per month for Zepbound, a once-weekly injection — matching the prices available through LillyDirect. Patients can complete a consultation on the Hims & Hers platform, receive a prescription if their provider determines it is appropriate, and have an FDA-approved Lilly medicine shipped directly to their home.
Ilya Yuffa, Executive Vice President and President of Lilly USA, said Lilly is always looking for new ways to help more people get the medicines they need, which means meeting patients where they already are; millions of people turn to Hims & Hers for their care, and through this agreement those patients now have a simpler, more direct way to get FDA-approved Lilly medicine at an affordable price if prescribed.
Andrew Dudum, co-founder and CEO of Hims & Hers, said he was proud that Hims & Hers is part of making sure more people can access the medicines Lilly has created. Under the agreement, Hims & Hers has never offered access to compounded copies of Lilly's GLP-1 medicines and has committed not to do so in the future; the companies have also committed to protecting independent clinical decision-making, so providers on the platform continue to prescribe the treatment they determine is right for each patient.
Reuters reported that Hims & Hers shares rose more than 7 percent in premarket trading after the deal was announced. Previously, patients on Hims & Hers could only reach Lilly's medicines by leaving the platform for LillyDirect.
来源：礼来公司
发布：GSM·美国（发布链接）
图片来源：图：礼来公司位于 Indianapolis 的总部大楼（资料图）。照片：Paul Sableman 摄，CC BY 2.0，经 Wikimedia Commons。 / Photo: Eli Lilly and Company headquarters in Indianapolis (file photo). Photo: Paul Sableman, CC BY 2.0, via Wikimedia Commons.
GSM Global · 本篇英文版 English edition of this story
